Triptans: Are they all the same?

Current Pain and Headache Reports

Volumn 6, Issue 2, 2002, Pages 140-146

  Pringsheim, Tamara ^a   Gawel, Marek ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cluster Headache; Migraine; Migraine Headache; Sumatriptan; Zolmitriptan

Indexed keywords

DRUG DERIVATIVE; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN;

CHEMISTRY; COMPARATIVE STUDY; DRUG INTERACTION; HEADACHE; HUMAN; METABOLISM; REVIEW;

DRUG INTERACTIONS; HEADACHE; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0036548049     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-002-0010-0     Document Type: Article

References (42)

1. Rapport MM, Green AA: Serum vasocontrictor (serotonin). Isolation and characterization. J Biol Chem 1948, 176:1243–1251.
2. Twarog BM, Page IH: Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 1953, 175:157–161.
3. Sicuteri F, Testi A, Anselmi B: Biochemical investigations in headache: increase in hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy Immunol 1961, 19:55–58. DOI: 10.1159/000229194
4. Anthony M, Hinterberger H, Lance JW: Plasma serotonin in migraine and stress. Arch Neurol 1967, 16:544–552.
5. Hamel E, Saxena PR: 5-Hydroxytriptamine involvement in migraine. In The Headaches, edn 2. Edited by Oleson J et al. Philadelphia, PA: Lippincott, Williams & Wilkins; 2000:319–324.
6. Goadsby PJ: The pharmacology of headache. Prog Neurobiol 2000, 62:509–525. An excellent review of the pharmacology of headache. DOI: 10.1016/S0301-0082(00)00010-1
7. Hamel E: The biology of serotonin receptors: focus on migraine pathophysiology and treatment. Can J Neurolog Sci 1999, 26(suppl3):S2-S6. Discusses the role of serotonin and serotonin receptors in migraine and how the triptans work.
8. Imitrex [package insert]. Research Triangle Park, NC: Glaxo Wellcome; 1999.
9. Amerge [package insert]. Research Triangle Park, NC: Glaxo Wellcome; 1998.
10. Cabarrocas X, Salva M: Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia 1997, 17:421.
11. Meloche J: Triptans and migraine: which drug for which patient? Can J Diagn 1999, January:67–77.
12. Dixon R, Warrander A: The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997, 17(suppl 18):15–20.
13. Johnson BF, Shah A, Law G: The absorption kinetics of eletriptan in migraineurs. Cephalalgia 1997, 17:415.
14. Maxalt [package insert]. Kirkland, Quebec, Canada: Merck Frosst; 1999.
15. Buchan P: The pharmacokinetics of frovatriptan, a potent selective 5-HT 1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers. Headache 1998, 5:376.
16. Hyland R, Jones BC, McCleverty P, et al.: In vitro metabolism of eletriptan in human liver microsomes. Cephalalgia 1998, 18:404.
17. Zomig [package insert]. Wilmington, DE: Astra Zeneca; 1998.
18. Axert [package insert]. Peapack, NJ: Pharmacia; 2001.
19. Rolan P: Potential drug interactions with the novel antimigraine compound zolmitriptan. Cephalalgia 1997, 17(suppl 18):21–27.
20. Mathew NT, Tietjen GE, Lucker C: Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 1996, 16:323–327. DOI: 10.1046/j.1468-2982.1996.1605323.x
21. Gardner DM, Lynd LD: Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother 1998, 32:33–38. DOI: 10.1345/aph.17204
22. Goldberg MR, Lowry RC, Musson DG, et al.: Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999, 39:192–199. DOI: 10.1177/00912709922007633
23. Smith DA, Cleary EW, Watkins S, et al.: Zolmitriptan does not interact with fluoxetine in healthy volunteers. Int J Clin Pharmacol Ther 1998, 36:301–305.
24. Milton KA, Tan L, Love R: The pharmacokinetic and pharmacodynamic interactions of oral eletriptan and propranolol in healthy volunteers. Paper presented at the 12th Migraine Trust International Symposium, London, September 1998; Abstract P59.
25. Buchan P, Ward C, Stewart AJ: The effect of propranolol on the pharmacokinetic and safety profiles of frovatriptan. Headache 1999, 39:A345.
26. Grujch N, Gawel M: Eletriptan. Expert Opin Invest Drugs 2001, 101:1869–1874. DOI: 10.1517/13543784.10.10.1869
27. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ: Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668–1675. A recent meta-analysis of the available triptans in acute migraine. DOI: 10.1016/S0140-6736(01)06711-3
28. Gawel MJ, Worthington I, Maggisano A: A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001, 28:30–41. A recent meta-analysis of sumatriptan, zolmitriptan, naratriptan, and rizatriptan.
29. Adelman JU, Lipton RB, Ferrari MD, et al.: Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001, 57:1377–1383. Comparison of rizatriptan, sumatriptan, zolmitriptan, and naratriptan in migraine.
30. Stark S, Spierings ELH, McNeal S, et al.: Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000, 40:513–520. DOI: 10.1046/j.1526-4610.2000.00082.x
31. Mathew NT, Kailasam J, Gentry P, Chernyshev O: Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000, 40:464–465. DOI: 10.1046/j.1526-4610.2000.00069.x
32. Lipton RB, Stewart WF: Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999, 39(suppl 2):S20-S26. DOI: 10.1111/j.1526-4610.1999.00006.x
33. Ryan R, Elkind A, Baker CC, et al.: Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997, 49:1225–1230.
34. Mathew NT, Asgharnejad M, Peykamian M, et al., on behalf of the Naratriptan S2WA3003 Study Group: Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double blind, placebo-controlled, crossover study. Neurology 1997, 49:1485–1490.
35. Klassen A, Elkind A, Asgharnejad M, et al., on behalf of the Naratriptan S2WA3001 Study Group: Naratriptan is effective and well-tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel group study. Headache 1997, 37:640–645. DOI: 10.1046/j.1526-4610.1997.3710640.x
36. Newman L, Mannix LK, Landy S, et al.: Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001, 41:248–256. DOI: 10.1046/j.1526-4610.2001.111006248.x
37. Sheftell F, O’Quinn S, Watson C, et al.: Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000, 40:103–110. DOI: 10.1046/j.1526-4610.2000.00015.x
38. Goldstein J, Ryan R, Jiang K, et al., and the Rizatriptan Protocol 046 Study Group: Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache 1998, 38:748–755. DOI: 10.1046/j.1526-4610.1998.3810748.x
39. International 311C90 long-term study group: The long-term tolerability and efficacy of oral zolmitriptan (ZOMIG,311C90) in the acute treatment of migraine. An international study. Headache 1998, 38:399–400.
40. Bahra A, Gawel MJ, Hardebo JE, et al.: Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology 2000, 54:1832–1839.
41. Colman SS, Brod MI, Krishnamurthy A, et al.: Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001, 23:127–145. DOI: 10.1016/S0149-2918(01)80036-9
42. Goldstein J, Keywood C, Hutchison J: Low 24 hour recurrence during treatment with frovatriptan. Cephalalgia 1999, 19:365–366.